[Examples of results of pharmaceutical cerebrovascular protection, with special emphasis on the statins]

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Context:

• Hypercholesterolemia is not a direct stroke risk factor, but lipid management is crucial for secondary prevention.
• Stroke and TIA patients require intensive LDL-cholesterol reduction below 1.8 mmol/L for effective statin therapy.
• Existing research explores the efficacy of various lipid-lowering agents beyond statins.

Purpose:

• To review the role of statins and other lipid-modifying therapies in stroke prevention.
• To highlight the importance of intensive LDL-cholesterol lowering in secondary stroke prevention.
• To discuss the potential benefits of fibrates, fish oil, and pleiotropic effects of antihypertensives/antidiabetics.

Summary:

• Statins effectively reduce stroke events, particularly in secondary prevention when LDL-cholesterol is <1.8 mmol/L, often requiring intensive treatment.
• Fibrates and fish oil demonstrate beneficial impacts in primary and secondary stroke prevention settings, respectively.
• Pleiotropic effects of certain antihypertensive and antidiabetic medications may also contribute to reducing cerebrovascular events.

Impact:

• Provides evidence-based recommendations for optimizing lipid management in stroke prevention.
• Informs clinical practice regarding the necessity of intensive lipid-lowering strategies post-stroke or TIA.
• Suggests a broader therapeutic approach including non-statin agents and medications with pleiotropic effects for cerebrovascular event reduction.